Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...

Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...

Vertex Pharmaceuticals (VRTX) announced that Health Canada has granted Marketing Authorization for ALYFTREK, a new triple combination therapy for ...

Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Bottom-up k-vertex connected component (k- VCC) enumeration methods, referred to as VCCE-BU, have exhib-ited better efficiency compared to the exact top-down k- VCC enumeration method (VCCE-TD).

Summit Midstream Corporation (NYSE: SMC) ("Summit", "SMC" or the "Corporation") announced today that its 2024 Schedule K-3 packages for Summit Midstream Partners, LP are now available online ...

HOUSTON, July 9, 2025 /PRNewswire/ -- Summit Midstream Corporation (NYSE: SMC) ("Summit", "SMC" or the "Corporation") announced today that its 2024 Schedule K-3 packages for Summit Midstream ...

Eastman Schedules Second-Quarter 2025 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast, and Release of Additional Information ...

The results of the review will need to be reflected in its financial statements for fiscal 2025 in the Company's Annual Report on Form 10-K.